The role of D2 vitamin metabolite paricalcitol in nephroprotective strategy in chronic disease of the kidneys
- 作者: Milovanov Y.S.1, Kozlovskaya L.V.1, Milovanova L.Y.1, Milovanov Y.S2, Kozlovskaya LV2, Milovanova LY.2
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University
- 期: 卷 83, 编号 6 (2011)
- 页面: 70-73
- 栏目: Editorial
- ##submission.dateSubmitted##: 10.04.2020
- ##submission.datePublished##: 15.06.2011
- URL: https://ter-arkhiv.ru/0040-3660/article/view/30888
- ID: 30888
如何引用文章
全文:
详细
作者简介
Yuriy Milovanov
Email: yumil2010@rambler.ru
Lidiya Kozlovskaya
Email: lkoslovckay@mail.ru
Lyudmila Milovanova
Email: lussya2000@mail.ru
Yu Milovanov
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
L Kozlovskaya
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
L Milovanova
I.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical University
参考
- Agarwal R., Acharya M., Tian J. et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 (6): 2823-2828.
- Coyne D., Acharya M., Qiu P. et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am. J. Kidney Dis. 2006; 47 (2): 263-276.
- Krajisnik T., Bjorklund P., Marsel R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1-alfa-hydroxylaseexpression in cultured bovine parathyroid cells. J. Endocrinol. 2007; 195: 125-131.
- Sprague S. M., Liach F., Amdahl M. et al. Paricacitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003; 64 (4): 1483-1490.
- Lindberg J., Martin K. J. et al. A long-term, multicenter study of the efficacy and safety of parycalcitol in end-stage renal disease. Clin. Nephrol. 2001; 56 (4): 315-323.
- Teng M., Wolf M., Lowrie E. et al. Survival of patients undergoing hemodialysis with paricacitol or calcitriol therapy. N. Engl. J. Med. 2003; 349 (5): 446-456.
- Martin K. J., Gonzalez M. G. et al. 19-Nor-1-a-25 Dihydroxyvitamin D2 (Paricalcitol) safety and affectively reduces the levels of the intact Parathyroid Hormone in patients on Hemodialysis. J. Am. Soc. Nephrol. 1998; 9: 1427-1432.
- Liach F., Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis. 2001; 38 (Suppl. 5): S45-S50.
- Schumock G. T. Comparative effectiveness of aricalcitol versus cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Nephron Clin. Pract. 2010; 117 (2): 151-159.
- Dobrez D. G., Mathes A., Amdahl M. et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitrioltreated patients in real-world clinical settings. Nephrol. Dial. Transplant. 2004; 19: 1174-1181.
- Schumack G. T., Arruda J. A. L., Marx S. E. et. al. Economic comparison of paricalcitol and calcitriol in the treatment of secondary hyperparathyroidism impact of hospitalization and survival. J. Med. Econ. 2007; 10: 393-409.
补充文件
![](/img/style/loading.gif)